Eli Lilly and Company announced executive leadership changes and the creation of neuroscience and immunology business units. These changes will increase Lilly's focus on introducing breakthrough new medicines to millions of people with unmet needs.
Eli Lilly has received approval in Germany for Axiron (estosterone solution 2%) for testosterone replacement therapy for male Hypogonadism when...
Boehringer Ingelheim and Eli Lilly and Company announced the FDA has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining...
To improve the understanding and advance the treatment of migraine, Eli Lilly and Company presented data on unmet needs in migraine from the OVERCOME (U.S.) study and on its portfolio of migraine medicines during the American Headache Society (AHS) 2021 Virtual Annual Scientific Meeting, June 3-6 .
Eli Lilly and Company and Incyte Corporation announced that Lilly has submitted a new drug application (NDA) to the FDA...
Sanofi and Eli Lilly and Company announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently...
Eli Lilly and Company has provided an update on the next steps planned for solanezumab, its Phase III monoclonal antibody...
SQUIRE, a newly-completed Phase III study of LY 801221 (necitumumab), from Eli Lilly, met its primary endpoint in patients with...
Eli Lilly and Company and Sigilon Therapeutics, Inc. announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases. Since 2018, Lilly and Sigilon have worked together to develop encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes
Eli Lilly and Company announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1...